UBT251: Novo Nordisk's Triple Agonist With 19.7% Weight Loss

UBT251 is Novo Nordisk's answer to retatrutide, and Novo did not invent it. The molecule is a once-weekly triple agonist of the GLP-1, GIP, and glucagon receptors, developed by United Biotechnology in China and licensed to Novo in March 2025 for $200 million upfront and up to $1.8 billion in milestones. In February 2026 the Chinese Phase 2 obesity trial reported mean weight loss of 19.7% at 24 weeks — a figure that, taken at face value, is the fastest weight loss any incretin drug has reported at that timepoint.

Taken at face value is doing a lot of work in that sentence. The 19.7% comes from 205 participants in a single country, has not been peer-reviewed, and was disclosed in a press release that omitted most of the numbers needed to interpret it. What follows is what UBT251 has actually shown, what it has not, and why Novo is spending a lot of money to find out.

What UBT251 Is: Three Receptors, One Peptide

UBT251 is a long-acting synthetic peptide that activates three receptors simultaneously. Each contributes something different.

GLP-1 agonism suppresses appetite and slows gastric emptying — the mechanism behind semaglutide. GIP agonism adds complementary effects on nutrient partitioning and adipose function, and appears to soften gastrointestinal side effects, which is what allows tirzepatide to be pushed to doses a pure GLP-1 agonist could not tolerate. The glucagon arm is the one that changes the arithmetic: rather than only reducing intake, glucagon receptor agonism raises energy expenditure and drives hepatic fat oxidation.

Evidence: "In both mice and humans, glucagon administration enhances energy expenditure and suppresses food intake suggesting a promising metabolic utility." — Novikoff A, Müller TD. Peptides. 2023;165:171003. DOI: 10.1016/j.peptides.2023.171003

That is the entire thesis behind the triple-agonist class. Appetite suppression alone runs into a ceiling because the body defends its weight by lowering energy expenditure as fat mass falls. Adding glucagon is an attempt to push against that adaptation from the other side. Retatrutide is the class benchmark; mazdutide and survodutide pursue the same logic with GLP-1/glucagon dual agonism, skipping GIP.

UBT251 is being developed across four indications — obesity, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, and chronic kidney disease. United Biotechnology retains rights in mainland China, Hong Kong, Macau, and Taiwan; Novo holds everything else.

The Phase 2 Obesity Result: 19.7% at 24 Weeks

The Chinese Phase 2 trial (NCT07177469) randomized 205 adults to weekly subcutaneous UBT251 at 2 mg, 4 mg (two different escalation schedules), or 6 mg, or placebo, for 24 weeks. It completed in October 2025 and reported in February 2026.

Phase 2 obesity trial (China)	Detail
Participants	205 adults
Eligibility	BMI ≥28, or 24–<28 with ≥1 weight-related comorbidity
Mean baseline weight / BMI	92.2 kg / 33.1 kg/m²
Duration	24 weeks
Top dose (6 mg) weight loss	19.7% (−17.5 kg)
Placebo	2.0% (−1.6 kg)
Placebo-adjusted	17.7 percentage points

For scale: retatrutide's Phase 2 obesity trial, the most directly comparable dataset in the class, produced 17.5% at 24 weeks at its 12 mg dose.

Evidence: "The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was −7.2% in the 1-mg group, −12.9% in the combined 4-mg group, −17.3% in the combined 8-mg group, and −17.5% in the 12-mg group, as compared with −1.6% in the placebo group." — Jastreboff AM, Kaplan LM, Frías JP, et al. New England Journal of Medicine. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972

So UBT251 nominally beat the benchmark at the same timepoint. That comparison is worth exactly as much as the caveats allow, and the caveats are substantial.

What the trial did not report

The company disclosure gave a headline number and a safety adjective. It did not give dose-by-dose results below 6 mg, discontinuation rates, responder rates at any threshold, or — critically — which estimand produced the 19.7%. That last omission matters more than it sounds. Reporting weight loss among participants who stayed on the drug (the efficacy estimand) routinely yields one to three percentage points more than reporting it across everyone randomized (the treatment-regimen estimand). Retatrutide's 17.5% is a least-squares mean from a peer-reviewed trial with the analysis specified. UBT251's 19.7% is a number in a press release. They are not yet the same kind of object.

Mean baseline weight was also 92.2 kg, lighter than the populations in the pivotal Western obesity trials. Because these results are expressed as percentages, baseline weight and body composition can move the headline without any difference in drug effect. The evidence that East Asian trials systematically inflate this class is genuinely weak — the direction varies by molecule, as the ribupatide record shows — but "not systematically biased" is a far weaker claim than "will replicate."

Adverse events were described as predominantly gastrointestinal, mostly mild to moderate, and diminishing over time. That is the standard characterization for every drug in this class and carries no information about whether 6 mg is tolerable for a year.

The Diabetes Trial Is the More Informative One

The Phase 2 type 2 diabetes study (NCT07163624) is the better dataset, for one reason: it had an active comparator. 211 Chinese adults with a mean baseline HbA1c of 8.12% received UBT251 or semaglutide 1.0 mg or placebo for 24 weeks.

Outcome at 24 weeks	UBT251 (top dose)	Semaglutide 1.0 mg	Placebo
HbA1c reduction	2.16%	1.77%	0.66%
Weight loss	9.8%	4.8%	1.4%

Beating semaglutide 1.0 mg on glycemic control by roughly 0.4 percentage points, and doubling its weight loss, is a real signal — and unlike the obesity trial, it is a within-trial comparison, immune to the population and estimand problems that make cross-trial numbers slippery. Waist circumference, blood pressure, and lipids all improved versus placebo.

The context is that semaglutide 1.0 mg is a diabetes dose, not an obesity dose. Doubling its weight effect is what a triple agonist should do. For reference, retatrutide's Phase 3 diabetes trial produced larger absolute glycemic effects in a longer study.

Evidence: In TRANSCEND-T2D-1, 537 adults with type 2 diabetes inadequately controlled on diet and exercise received retatrutide or placebo for 40 weeks; HbA1c fell 1.94% and body weight 15.3% at the 12 mg dose, versus 0.81% and 2.6% on placebo. — Bajaj HS, Welch M, Shah P, et al. The Lancet. 2026;407(10546):2402-2413. DOI: 10.1016/S0140-6736(26)00967-0

How UBT251 Compares With the Rest of the Field

Drug	Receptors	Reported weight loss	Duration	Status
Semaglutide 2.4 mg	GLP-1	14.9%	68 wks	Approved
Tirzepatide 15 mg	GLP-1 + GIP	20.9%	72 wks	Approved
Survodutide 4.8 mg	GLP-1 + glucagon	14.9%	46 wks	Phase 3
Mazdutide 6 mg	GLP-1 + glucagon	14.0%	48 wks	Approved (China)
Retatrutide 12 mg	GLP-1 + GIP + glucagon	24.2%	48 wks	Phase 3
UBT251 6 mg	GLP-1 + GIP + glucagon	19.7%	24 wks	Phase 2 / Phase 3 (China)

The column that makes UBT251 interesting is duration, not magnitude. Every other entry needed 46 weeks or more to reach its number. UBT251 reached 19.7% in 24. Weight loss in this class has not plateaued at six months in any trial that has looked, so the open question is where the curve goes with another six months of dosing — and no one has that data yet.

The comparison also flatters UBT251 in a way that should be named: these are different trials, different populations, and in several cases different estimands. The table is a map of the field, not a ranking.

What Novo Nordisk Is Actually Doing With It

Novo's behavior is more informative than any press release. Since acquiring rights, it has started a global Phase 2 in the US and Canada (NCT07395687) enrolling 333 participants across three parts, with weight change at 28 weeks as the efficacy endpoint and primary completion set for January 2027. That trial exists to answer the population question directly.

It has also begun the unglamorous regulatory groundwork that only happens for assets a sponsor intends to file: drug-drug interaction studies with midazolam, caffeine, and warfarin (NCT07710768), and a study of UBT251's effect on oral contraceptives and gastric emptying (NCT07710729) — the same question that matters for every drug that slows the stomach, covered in more depth in GLP-1 medications and birth control.

In China, United Biotechnology moved to Phase 3 in July 2026: a 600-participant obesity trial (NCT07648225) running to late 2027, plus two diabetes trials, UNIGUIDE-1 and UNIGUIDE-2, enrolling 360 and 956. Phase 2 studies in MASH and chronic kidney disease are recruiting.

Global pivotal data are not close. A Novo Phase 2 reading out in 2027 puts Phase 3 initiation in 2027 at the earliest and readouts around 2029 — by which time retatrutide will likely have been on the market for years.

What Glucagon Agonism Costs

Glucagon is not a free lunch, and the class has three known liabilities.

Heart rate. Dose-dependent increases in heart rate appeared in retatrutide's Phase 2, peaking at 24 weeks before declining. This is a class effect of incretin therapy generally, discussed in GLP-1 medications and heart rate, but the glucagon component adds a thermogenic driver on top of it.

Glycemic effects. Glucagon raises blood glucose. In these molecules the GLP-1 and GIP arms more than compensate — UBT251 cut HbA1c by 2.16% — but the balance depends on the ratio of receptor activity, which is why dose-finding in this class is unusually consequential.

Tolerability at the top dose. Survodutide's Phase 2 is the cautionary example: only 60.4% of participants completed 46 weeks, with gastrointestinal events in 75% of those on drug. A 24-week trial in 205 people has not tested UBT251 against that failure mode.

On muscle loss, the class evidence is mildly reassuring. A DXA substudy of retatrutide found fat mass reductions of 26.1% at 8 mg versus 4.5% on placebo, with the ratio of lean mass loss to total weight loss comparable to other obesity treatments.

Evidence: "The proportion of lean mass loss to weight loss was similar to other obesity treatments. These findings could provide reassurance that a greater proportion of lean mass is not lost with retatrutide despite the overall increased weight loss." — Coskun T, Wu Q, Schloot NC, et al. Lancet Diabetes & Endocrinology. 2025;13(8):674-684. DOI: 10.1016/S2213-8587(25)00092-0

No equivalent body-composition data exist for UBT251.

Key Takeaways

UBT251 produced 19.7% mean weight loss at 24 weeks in 205 Chinese adults, nominally the fastest result any incretin drug has reported at that timepoint, and beat semaglutide 1.0 mg head-to-head on both HbA1c and weight in a separate diabetes trial. Novo Nordisk committed up to $2 billion to the asset before either result was public.

None of it is peer-reviewed. Dose-level results, discontinuation rates, responder rates, and the estimand behind the headline number have not been disclosed, and every efficacy figure comes from one country at doses tested for six months.

What to watch: whether Novo's US and Canadian Phase 2 reproduces the effect size in a heavier population when it reads out in 2027; whether 6 mg holds up past 24 weeks or tolerability caps the dose the way it appeared to for survodutide; and whether the Chinese Phase 3 reports the completeness of data the Phase 2 withheld. Until then UBT251 is a promising molecule with a thin public evidence base — and, like every drug in this class, it will inherit the problem that weight regain after stopping is a property of the biology rather than of any particular receptor combination.

References

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972
Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529-544. DOI: 10.1016/S0140-6736(23)01053-X
Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet. 2026;407(10546):2402-2413. DOI: 10.1016/S0140-6736(26)00967-0
Novikoff A, Müller TD. The molecular pharmacology of glucagon agonists in diabetes and obesity. Peptides. 2023;165:171003. DOI: 10.1016/j.peptides.2023.171003
le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes & Endocrinology. 2024;12(3):162-173. DOI: 10.1016/S2213-8587(23)00356-X
Ji L, Jiang H, Bi Y, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1). New England Journal of Medicine. 2025;392(22):2215-2225. DOI: 10.1056/NEJMoa2411528
Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes & Endocrinology. 2025;13(8):674-684. DOI: 10.1016/S2213-8587(25)00092-0
Son JW, le Roux CW, Blüher M, et al. Novel GLP-1-based medications for type 2 diabetes and obesity. Endocrine Reviews. 2026;47(2):159-177. DOI: 10.1210/endrev/bnaf036
The United Laboratories International Holdings and Novo Nordisk. UBT251 phase 1b, phase 2 obesity (NCT07177469) and phase 2 type 2 diabetes (NCT07163624) topline results; global phase 2 (NCT07395687) and Chinese phase 3 (NCT07648225) trial registrations. Company-reported data announced February 24 and March 25, 2026 — not peer-reviewed.

Last updated: 2026-08-04 Medical review: Dr. James Chen, MD, PhD, FACE